SCHEMBL4038868

SCHEMBL4038868

Cc1cc(C)cc(Nc2nc(N)n(-c3nc4ccccc4s3)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.56
MAPK1 P28482 2/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
AXL P30530 2/20 0.48
RAB9A P51151 6/20 0.47
MAPT P10636 5/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
NPC1 O15118 5/20 0.47
ALDH1A1 P00352 3/20 0.47
TP53 P04637 1/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HTT P42858 1/20 0.45
FLT3 P36888 2/20 0.43
DUSP3 P51452 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12780930 0.91 BACE1 (0.54) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL12780946 0.89 BACE1 (0.62) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL12780866 0.87 BACE1 (0.64) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL12779066 0.87 BACE1 (0.63) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL12780950 0.86 BACE1 (0.56) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL12781000 0.86 BACE1 (0.56) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL4043057 0.85 BACE1 (0.58) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL12780839 0.84 FLT3 (0.66) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL12780898 0.82 BACE1 (0.62) BACE1MAPK1MEN1KMT2AAXL
SCHEMBL12780980 0.82 BACE1 (0.62) BACE1MAPK1MEN1KMT2AAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885MAPK1 95/4885MEN1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.